<div id="readability-page-1"><p>In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on cbdMD, with a price target of <span id="expert-recommendation-target">$2.00</span>.</p><h3>Claim 70% Off TipRanks This Holiday Season</h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>According to TipRanks, Vendetti is an analyst with an average return of <span>-24.3%</span> and a 23.64% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Nuwellis, Milestone Scientific, and Clinigence Holdings.</p> <p>Currently, the analyst consensus on cbdMD is a Moderate Buy with an average price target of $2.00.</p></div>

YCBD

<p>Maxim Group's Anthony Vendetti maintained a Buy rating on cbdMD with a price target of $2.00. Vendetti, who has an average return of -24.3% and a 23.64% success rate, focuses on the Healthcare sector. The analyst consensus on cbdMD is a Moderate Buy with an average price target of $2.00.</p>

Maxim Group Keeps Their Buy Rating on cbdMD (YCBD)